Home >> News >> Naloxone Market is Expected to grow at a CAGR of 10.1% during the forecast period of 2022-2030

Naloxone Market is Expected to grow at a CAGR of 10.1% during the forecast period of 2022-2030

Naloxone is an opioid antagonist designed to rapidly reverse opioid overdose. Naloxone can restore the normal respiration of a person whose breathing has stopped or slowed down due to opioid or heroin overdose. Currently, opioid abuse is one of the foremost causes of drug overdose and is a leading cause of death globally. However, it is more common in North America and Europe. The opioid crisis in the U.S. has reached epidemic proportions, leading to serious healthcare costs and losses of resources. The urgent need for better treatment and growth in numbers of people suffering from opioid dependence is resulting in the growth in the U.S. naloxone market. Opioid dependence is a serious concern globally, with more than 25 million people affected. The problem exists in both developed as well as developing countries but is greatest in the United States. Global naloxone market is expected to grow at a CAGR of 10.1% during the forecast period of 2022-2030.

Based on the formulation/route of administration, the naloxone market is categorized as parenteral, intranasal, and sublingual. The parenteral segment contributed highest to the market revenues. Hospitals still remain the key resort when individuals are overdosed, and parenteral remains the key preferred administration method among healthcare professionals. The sublingual route stands second followed by the parenteral route. Sublingual options have been tested and efficiency proven across decades and also, intake does not require the help of a healthcare professional. Therefore, this route is convenient for emergency use. However, during the forecast period, there have been significant changes in the market compared to the base year of 2020.  

Browse the complete report with TOC at https://www.acutemarketreports.com/report/naloxone-market

With respect to sales channels, the market is segmented based on hospital pharmacy, outpatient retail pharmacy, online pharmacy, and others. Hospital pharmacies were the prime point of sales for naloxone in 2021, as the primary place of emergency treatment is still hospitals. For individuals who do not require hospitals, outpatient retail pharmacies remain the key point of sales. Online and other channels were not significantly popular in 2021. However, there are significant changes expected in the market trend during the forecast period of 2022 to 2030.  

In terms of geography, the U.S. holds the largest market owing to having the largest number of substance addicts vis a vis awareness for available options to reverse the ill effects of an overdose. Latin America is followed by North America. However, concerning awareness levels and accessibility to high-end therapeutic options, this region falls behind in comparison to North America. APAC is a comparatively new market that has a huge scope for growth in the coming decade. China and the rest of Asia are seen as significant markets that promise potential during the forecast period. APAC is evidencing an increased per capita income that makes access to opioids easy. Awareness of options for reversing opioid overdose is further expected to boost the revenues of this region during the forecast period. The key regions that are promising growth in Asia include China, Japan, Australia, Korea, and others.

Request Sample Copy from https://www.acutemarketreports.com/request-free-sample/138444

Indivior remains at the top position with respect to product portfolio and business strength. Currently Indivior hold maximum number of products directly and indirectly related to naloxone, for instance, Suboxone, Sublocade and Subutex. Soboxne patent has expired and hence generic products are being introduced in the market. The key strategies followed by the company includes collaborations to understand the key market segments. For instance, Virginia Tech and Indivior Announce New Collaboration to Study Long-Term Recovery in People with Opioid Use Disorder. The company also received approval for SUBUTEX® prolonged release solution for injection, 100mg and 300mg for substitution treatment of opioid dependence in Sweden. The company is also significantly active in tackling stigma in patients with opioid use disorder.

KEY MARKET MOVEMENTS

  • Global naloxone market is expected to grow at a CAGR of 10.1% during the forecast period of 2022-2030.
  • The parenteral segment contributed highest to the market revenues.
  • The sublingual route stands second followed by the parenteral route.
  • Hospital pharmacies were the prime point of sales for naloxone in 2021, as the primary place of emergency treatment is still hospitals.
  • In terms of geography, the U.S. holds the largest market owing to having the largest number of substance addicts vis a vis awareness for available options to reverse the ill effects of an overdose.
  • APAC remains as the fastest growing markets for naloxone during the forecast period.
  • Indivior remains at the top position with respect to product portfolio and business strength.
ATTRIBUTEDETAILS
Research Period2020-2030
Base Year2021
forecast Period2022-2030
Historical Year2020
Unit USD Million
Segmentationby Route Of Administration (2020-2030; US$ Mn)
by Dosage (2020-2030; US$ Mn)
by Sales Channel (2020-2030; US$ Mn)
by Region (2020-2030; US$ Mn)
by Covid-19 Impact Segment (2020-2030; US$ Mn)

Visit related research reports: https://www.acutemarketreports.com/category/market-research

About Us
Acute Market Reports is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives.

Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US
(US/CANADA) Ph.: +1-855-455-8662
E-mailsales@acutemarketreports.com

Leave a Reply

Your email address will not be published. Required fields are marked *